[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"folliculotropic-mycosis-fungoides\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:folliculotropic-mycosis-fungoides":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,60],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100054160","phase-1-durvalumab-with-or-without-lenalidomide-in-treating-patients-with-relapsed-or-refractory-cutaneous-or-peripheral-t-cell-lymphoma-100054160",false,"NCT03011814","Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma","A Phase 1\u002F2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed\u002F Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n* Registered into Revlimid REMS program\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Fully recovered from acute toxicities (except alopecia) of all prior therapies to Common Terminology Criteria for Adverse Events (CTCAE) =\\\u003C grade 1\n* Relapsed\u002Frefractory disease\n* Failed \\>= 2 prior systemic therapies \\*NOTE: For systemic ALCL prior systemic therapy must also include progression on brentuximab vedotin\n\nCUTANEOUS T-CELL LYMPHOMA (CTCL) ONLY\n\n* Histologically confirmed mycosis fungoides (MF) or Sezary syndrome (SS); Phase 1: \\>= stage IIB OR \\>= stage IB-IIA folliculotropic\u002Ftransformed MF; Phase 2: \\>= stage IB\n\n  * Stage of disease according to TNMB classification\n  * Pathology report must be diagnostic or be consistent with MF\u002FSS criteria\n  * SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathological features, the diagnosis may be based on either node biopsy or fulfillment of B2 criteria\n  * For MF where the histological diagnosis by light microscopic examination is not confirmed, diagnostic criteria that has been recommended by the International Society of Cutaneous Lymphomas (ISCL) should be used\n* Measurable disease per modified severity weighted assessment tool (mSWAT) and\u002For Sezary count\n* Baseline skin biopsy taken within 6 months available for central review submission\n\nPERIPHERAL T-CELL LYMPHOMA (PTCL) ONLY\n\n* Histologically confirmed PTCL as defined by World Health Organization (WHO) 2008 criteria\n* Measurable and\u002For evaluable disease per Lugano Classification\n* Absolute neutrophil count (ANC) \\>= 1000\u002Fmm\\^3\n\n  \\* Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement\n* Platelets \\>= 100,000\u002Fmm\\^3\n\n  \\* Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement\n* Total serum bilirubin =\\\u003C 2.2 mg\u002FdL\n* Aspartate aminotransferase (AST) =\\\u003C 2 x upper limit of normal (ULN)\n* Alanine aminotransferase (ALT) =\\\u003C 2 x ULN\n* Creatinine clearance of \\>= 60 mL\u002Fmin per the Cockcroft-Gault formula\n* If not receiving anticoagulants: international normalized ratio (INR) AND prothrombin (PT) =\\\u003C 1.5 x ULN\n\n  \\* If on anticoagulant therapy: PT must be within therapeutic range of intended used of anticoagulants\n* Female of childbearing potential: negative urine or serum pregnancy test\n\n  \\* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Female of child bearing potential: willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 90 days after the last dose of study medication\n\n  \\* Childbearing potential defined as not being surgically sterilized or have not been free from menses for \\> 1 year\n* Male: use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy\n\nExclusion Criteria:\n\n* Immunotherapy with immune checkpoint inhibitors, cell-based therapies, or cancer vaccines\n* Lenalidomide, thalidomide or other immunomodulatory drugs (IMiDs)\n* Monoclonal antibody within 5 half-lives of the antibody prior to initiating protocol therapy\n* Any systemic therapy, including monoclonal antibody within 28 days or 5 half-lives (whichever is shorter) of initiating protocol therapy\n* Any skin-directed therapy within 14 days prior to initiating protocol therapy\n* Any radiation therapy within 21 days prior to initiating protocol therapy\n* Immunosuppressive medication within 14 days prior to the first dose of study treatment; the following are exceptions to this criterion:\n\n  * Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection) and are on stable dose for at least 28 days\n  * Systemic corticosteroids at physiologic doses of \\\u003C 10 mg\u002Fday of prednisone or equivalent\n* Live, attenuated vaccine within 30 days prior to the first dose of protocol therapy\n* History of pneumonitis (non-infectious) that required steroids or current pneumonitis\n* Disease free of prior malignancies for \\>= 5 years with the exception of:\n\n  * Currently treated squamous cell and basal cell carcinoma of the skin\n  * Carcinoma in situ of the cervix, or\n  * Surgically removed melanoma in situ of the skin (stage 0) with histological confirmed free margins of excision or\n  * Prostate cancer (T1a or T1b using the TNM \\[tumor, nodes, metastasis\\] clinical staging system) that has\u002Fhave been surgically cured, or\n  * Any other malignancy that has\u002Fhave been curatively treated with surgery and\u002For localized radiation\n* Allergic reaction\u002F hypersensitivity to thalidomide or to the excipients contained in the formulation of durvalumab\n* Female only: pregnant or lactating\n* Prior stem cell transplantation\n* Acute infection requiring systemic treatment\n* Known history of human immunodeficiency virus (HIV) infection\n* Active hepatitis B or C infection\n* Conditions requiring chronic steroid or immunosuppressive treatment that likely need additional steroid or immunosuppressive treatments in addition to the protocol therapy\n* Current peripheral neuropathy \\>= grade 2\n* Renal failure requiring hemodialysis or peritoneal dialysis\n* Unstable cardiac disease as defined by one of the following:\n\n  * Cardiac events such as myocardial infarction (MI) within the past 6 months\n  * NYHA (New York Heart Association) heart failure class III-IV\n  * Uncontrolled atrial fibrillation or hypertension\n* Major surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatment\n* Active or prior documented autoimmune or inflammatory disorders requiring therapy within the past 3 years prior to the start of treatment; the following are exceptions to this criterion:\n\n  * Vitiligo or alopecia;\n  * Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; or\n  * Psoriasis not requiring systemic treatment\n* History of primary immunodeficiency\n* Incidence of gastrointestinal disease that may significantly alter the absorption of lenalidomide\n* Any other condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection\u002Finflammation, intestinal obstruction, unable to swallow medication, social\u002Fpsychological issues, etc\n* In the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)","ALL","18 Years",{"count":19,"type":20},78,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This randomized phase I\u002FII trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as durvalumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving durvalumab and lenalidomide may work better in treating patients with cutaneous or peripheral T cell lymphoma.",[27,28,29,30,31,32,33,34],"Folliculotropic Mycosis Fungoides","Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma","Recurrent Mycosis Fungoides","Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma","Refractory Mycosis Fungoides","Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified","Sezary Syndrome","Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":39},"2017-03-08",{"date":43,"type":20},"2030-04-14",{"name":45,"class":46},"City of Hope Medical Center","OTHER",4,{"id":49,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":25,"conditions":52,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":57,"leadSponsor":59,"locationsCount":47},"100286681",{"count":19,"type":20},[23,24],[27,28,29,30,31,32,33,34],"2026-06-15",{"date":55,"type":39},"2026-06-16",{"date":41,"type":39},{"date":58,"type":20},"2026-08-30",{"name":45,"class":46},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":21,"phases":69,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":5},"100433940","phase-2-extracorporeal-photopheresis-and-mogamulizumab-for-the-treatment-of-erythrodermic-cutaneous-t-cell-lymphoma-100433940","NCT04930653","Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma","A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative\n\n  * Assent, when appropriate, will be obtained per institutional guideline\n* Agreement to allow the use of archival tissue from diagnostic tumor biopsies\n\n  * If unavailable, exceptions may be granted with study principal investigator (PI) approval\n* Age: \\>= 18 years\n* Eastern Cooperative Oncology Group (ECOG) =\\\u003C 2\n* Histologically confirmed mycosis fungoides (MF) or Sezary syndrome (SS). Safety lead-in: \\>= stage IIB OR \\>= stage IB-IIA folliculotropic\u002Ftransformed MF. Phase 2: \\>= stage IB\n\n  * Stage of disease according to Tumor-Node-Metastasis-Blood (TNMB) classification\n  * Pathology report must be diagnostic or be consistent with MF\u002FSS criteria\n  * SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathologic features, the diagnosis may be based on either node biopsy or fulfillment of B2 criteria\n  * For MF where the histological diagnosis by light microscopic examination is not confirmed, diagnostic criteria that been recommended by the International Society of Cutaneous Lymphomas (ISCL) should be used.\n* Measurable disease per Modified Severity Weighted Assessment Tool (mSWAT) and\u002For Sezary count\n* Baseline skin biopsy taken within 6 months available for central review submission\n* Without bone marrow involvement: Absolute neutrophil count (ANC) \\>= 1,500\u002Fmm\\^3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n\n  * NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement\n* With bone marrow involvement: ANC \\>= 1,000\u002Fmm\\^3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n\n  * NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement\n* Without bone marrow involvement: Platelets \\>= 100,000\u002Fmm\\^3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n\n  * NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement\n* With bone marrow involvement: Platelets \\>= 75,000\u002Fmm3 (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n\n  * NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement\n* Total bilirubin =\\\u003C 1.5 x upper limit of normal (ULN) (unless has Gilbert's disease)(performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* Aspartate aminotransferase (AST) =\\\u003C 2.5 x ULN (unless has Gilbert's disease)(performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* Alanine aminotransferase (ALT) =\\\u003C 2.5 x ULN (unless has Gilbert's disease)(performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* Creatinine clearance of \\>= 60 mL\u002Fmin per 24 hour urine test or the Cockcroft-Gault formula (unless has Gilbert's disease) (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* If not receiving anticoagulants: International normalized ratio (INR) OR prothrombin (PT) =\\\u003C 1.5 x ULN (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* If not receiving anticoagulants: Activated partial thromboplastin time (aPTT) =\\\u003C 1.5 x ULN (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)\n* Hepatitis C virus (HCV)\\*, active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin \\[RPR\\])\n\n  * If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed\n* Meets other institutional and federal requirements for infectious disease titer requirements\n\n  * Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy\n* Subjects with MF and a history of staphylococcus colonization are eligible provided they continue to receive stable doses of prophylactic antibiotics\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Agreement by females and males of childbearing potential\\* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n\nExclusion Criteria:\n\n* Prior mogamulizumab\n* Any systemic therapy, including monoclonal antibody within 28 days or 5 half-lives (whichever is shorter) of initiating protocol therapy\n* Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days prior to day 1 of protocol therapy\n* Any skin-directed therapy within 14 days prior to initiating protocol therapy\n* Any radiation therapy within 21 days prior to initiating protocol therapy\n* Immunosuppressive medication within 14 days prior to the first dose of study treatment. The following are exceptions to this criterion:\n\n  * Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular injection) and are on stable dose for at least 28 days\n  * Systemic corticosteroids at physiologic doses of \\\u003C 10 mg\u002Fday of prednisone or equivalent\n* Live, attenuated vaccine within 30 days prior to the first dose protocol therapy\n* Disease free of prior malignancies for \\>= 5 years with the exception of:\n\n  * Currently treated squamous cell and basal cell carcinoma of the skin, or\n  * Carcinoma in situ of the cervix, or\n  * Surgically removed melanoma in situ of the skin (stage 0) with histological confirmed free margins of excision, or\n  * Prostate cancer (T1a or T1b using the TNM \\[tumor, nodes, metastasis\\] clinical staging system) that has\u002Fhave been surgically cured, or\n  * Any other malignancy that has\u002Fhave been curatively treated with surgery and\u002For localized radiation\n* Active infection requiring antibiotics\n* Known hepatitis B or hepatitis C infection\n* Other active malignancy\n* Females only: Pregnant or breastfeeding\n* Prior stem cell transplantation\n* Acute infection requiring systemic treatment\n* Conditions requiring chronic steroid or immunosuppressive treatment that likely need additional steroid or immunosuppressive treatments in addition to the protocol therapy\n* Renal failure requiring hemodialysis or peritoneal dialysis\n* Unstable cardiac disease as defined by one of the following:\n\n  * Cardiac events such as myocardial infarction (MI) within the past 6 months\n  * NYHA (New York Heart Association) heart failure class III-IV\n  * Uncontrolled atrial fibrillation or hypertension\n* Major surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatment\n* Active or prior documented autoimmune or inflammatory disorders requiring therapy within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:\n\n  * Vitiligo or alopecia\n  * Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; or\n  * Psoriasis not requiring systemic treatment\n* History of primary immunodeficiency\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)",{"count":68,"type":20},34,[24],"This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a widespread red rash that may cover most of the body. ECP is a medical treatment that removes blood with a machine, isolates white blood cells and exposes them to ultra violet light, then returns the cells to the body. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving mogamulizumab with ECP may work together to kill the tumor cells directly (with mogamulizumab) and boost immune response to cancer (with ECP).",[27,72,33,73,74,75,76,77],"Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8","Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8","Transformed Mycosis Fungoides","2025-10-10",{"date":80,"type":39},"2025-10-14",{"date":82,"type":39},"2022-10-19",{"date":84,"type":20},"2028-06-15",{"name":45,"class":46}]